A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.

Drew W. Rasco,Yufeng Li,Yuefen Tang,Lichuang Men,Hengbang Wang,Jiao Ji,Zhiyan Liang,Joan Sun,Alex Amaya,Yingjie Huang,Dajun Yang,Yifan Zhai

A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.

2019

Drew W. Rasco
Yufeng Li
Yuefen Tang
Lichuang Men
Hengbang Wang
Jiao Ji
Zhiyan Liang
Joan Sun
Alex Amaya
Yingjie Huang
Dajun Yang
Yifan Zhai

3125Background: APG-1387 is a novel, bivalent small molecule IAP (inhibitor of apoptosis proteins) inhibitor. It has shown strong antitumor activities in multiple human xenograft cancer models. APG...

Keywords:

Oncology
Pathology
Pembrolizumab
Internal medicine
Medicine
Bivalent (genetics)
Inhibitor of apoptosis
Small molecule
Cancer research
Cancer
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations